Risk factors for valproic acid resistance in childhood absence epilepsy  by Ollivier, May Lissa et al.
Seizure 18 (2009) 690–694Risk factors for valproic acid resistance in childhood absence epilepsy
May Lissa Ollivier a, Marie France Dubois b, Maja Krajinovic c, Patrick Cossette d, Lionel Carmant a,*
aDepartment of Paediatrics, Division of Neurology, CHU Sainte-Justine, 3175 Coˆte-Ste-Catherine, Montreal, Quebec, H3T 1C5 Canada
b Faculty of Medicine and Health Sciences, CHUS, University of Sherbrooke, 3001, 12ie`me Avenue Nord, Sherbrooke, Quebec, J1H 5N4 Canada
c Faculty of Medicine, University of Montreal, 2900 E´douard-Montpetit, Montreal, Quebec, H3T 1J4 Canada
d Faculty of Medicine, Department of Neurology, CHUM, 3840 rue Saint-Urbain, Montreal, Quebec, H2W 1T8 Canada
A R T I C L E I N F O
Article history:
Received 20 April 2009
Received in revised form 14 July 2009
Accepted 18 September 2009
Keywords:
Co-morbidity
Anticonvulsants
Refractory seizures
Pharmacoresistance
A B S T R A C T
Aims: Valproic acid (VPA) is reported to be effective for the control of absence seizures in 75% of children.
The aim of this study was to determine the clinical and socio-demographic factors associated with VPA
response in newly diagnosed childhood absence epilepsy (CAE) and to determine if these factors also
inﬂuence the chances of achieving long-term seizure freedom.
Methods: Medical charts of 180 children with CAE were retrospectively reviewed. Clinical, electro-
encephalographic and imaging ﬁndings were recorded to correlate with complete VPA response and
long-term epilepsy outcome. Factors associated with non-responsiveness were identiﬁed individually
and in a multivariable logistic regression analysis.
Results: Treatment was successful in 112 (58.3%) children. More children that were non-responsive to
VPA experienced generalized tonic clonic seizures (GTCS) (33.8% vs. 13.4% for responders; p = 0.001) and
52.9% had a pre-treatment seizure frequency greater than 10/day (vs. 27.0% for responders; p < 0.001).
Finally, responders were older at time of diagnosis versus non-responders (p = 0.001). Absence of long-
term seizure freedomwas linked to the presence of GTCS, the absence of initial response and the need for
multiple AEDs to control seizures.
Interpretation: Our results suggest that clinical phenotypes are associated with reduced response rates
to VPA. This should be taken into account when counselling families of children with newly diagnosed
absence epilepsy.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The proportion of patients with all types of epilepsy that are
pharmacoresistant varies from study to study but can be roughly
estimated to be around 30%.1–3 This percentage will vary
depending on the age of the cohort, proportion of each seizure
type and different treatments given. Many studies have attempted
to deﬁne the factors that could be responsible for refractory
epilepsy. Some of the identiﬁed factors include response to the ﬁrst
treatment,4,5 age at seizure onset,6,7 presence of generalized tonic
clonic seizures (GTCS),8 types of seizures or epilepsy2,6,7 and a large
number of pre-treatment seizures.1,7 These studies have used a
wide range of diagnostic criteria as well as variable therapies. And
most of them have actually focused on factors predicting a lack of
long-term remission.6,9* Corresponding author. Tel.: +1 514 345 4653; fax: +1 514 345 4787.
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(M. Krajinovic), patrick.cossette@umontreal.ca (P. Cossette),
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doi:10.1016/j.seizure.2009.09.007Childhood absence epilepsy (CAE) is one of the most common
forms of epilepsy in young children. It accounts for 10–15% of all
childhood epilepsies.10 A peak in incidence can be observed in
children that are 5–7 years old11 and it is slightly more common in
girls than boys.11,12 CAE is characterised by absence seizures (AS)
that are brief, with no post-ictal phase and occurmany times a day.
These can also be accompanied by GTCS ormyoclonic seizures.11,13
All idiopathic absence epilepsies are due to a disruption of
thalamo-cortical networks. The 3 Hz spike and wave discharges
have been shown by Steriade and collaborators as originating from
sleep oscillation generators.14,15 Therefore one would predict that
since absence epilepsy is a well-deﬁned clinical and pathophy-
siological entity, a single drug should be effective for all children
with CAE.
Valproic acid (VPA) is often considered to be the drug of choice
for the treatment of CAE16,17 even though it is still unclear if it is
more effective than ethosuximide (ESM) or lamotrigine (LTG).18
Population based studies have shown that VPA can control AS in
about 75% of children with CAE.12 The remaining 25% continue to
have seizures on VPA or experience side effects limiting its
utilisation. In our study, we wanted to identify factors that would
predict not only long-term outcome but also the initial VPAvier Ltd. All rights reserved.
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remission.19
The aim of this study was to determine the clinical and socio-
demographic factors associated with VPA response in children
newly diagnosed with CAE and to determine if these factors also
inﬂuence the chances of achieving long-term seizure freedom.
2. Patients and methods
2.1. Patients
The CHU Sainte Justine (Universite´ de Montre´al, Canada) offers
tertiary care and specialized clinics for patients with newly
diagnosed and refractory epilepsy from the greater Montreal area
as well as from remote areas in the province of Quebec. All patients
are referred to the neurologist by pediatric and ER doctors as well
as general practitioners. They are ﬁrst seen during the new
diagnosis clinic and then followed during regular clinic periods for
treatment and follow-up. Patients younger than 18 years old at
time of diagnosis of idiopathic CAE and treated at the CHU Sainte
Justine between 2000 and 2008 were retrospectively identiﬁed.
Potential candidates were identiﬁed by EEG and chart review. All
patients that met the diagnosis criteria of CAE (according to the
ILAE20) and that had been treated with VPA (Epival1, Depacon1,
Depakene1 or Depakote1) were included in the study. The
standard protocol for VPA treatment at the CHU Sainte Justine
consists of an initial dose of 30 mg/kg/day that can be titrated up to
60 mg/kg/day depending on the patient’s response, tolerance and
plasma levels. EEGs with hyperventilation are performed periodi-
cally for all patients. We excluded all patients who had known
brain lesions. Developmental delay and attention deﬁcit disorder
were the only two accepted neurological comorbidities. One
hundred and eighty children met our study criteria and were
therefore included in our sample. Medical charts of these patients
were reviewed in order to determine their responsiveness to VPA
and to identify clinical factors potentially related to its response.
2.2. Methods
Clinical and socio-demographical information were extracted
by chart review. Variables included sex, all prenatal complications,
perinatal history (including prematurity), febrile seizures, family
history of epilepsy, age at AS onset, age at treatment onset, seizure
frequency prior and after treatment onset, VPA efﬁcacy and serum
concentration, other AEDs used as well as other medications not
related to epilepsy, coexisting seizure types (GTC or myoclonic
seizures), presence of a learning disability, and ﬁnally the presence
or absence of a long-term seizure freedom. The initial EEGs were
only used to conﬁrm the clinical diagnosis and were not used as a
variable in the prediction of outcome.
2.3. Deﬁnitions
Seizure frequency was the average number of seizures per day
prior to treatment and following the treatment as deﬁned by the
parents. It was categorized as less than 10 seizures per day and 10
or more per day. Response to treatment was considered to be a
complete disappearance of AS during VPA treatment. A normal EEG
during VPA treatment was also a sine qua non criterion for
response. A patientwas considered to be refractory to VPA if he/she
continued to experience absence seizures despite a therapeutic
VPA level. A patient was considered seizure free if the parents did
not report any seizures, no seizures were apparent during
hyperventilation and the EEG was normal. We then divided this
group into two categories which were seizure free without
medication and seizure free but still on medication. The lattercorresponded to patientswhowere seizure free but the neurologist
decided to pursue the treatment formore than 2 years after the last
seizure to better the chances of remission.
2.4. Statistical methods
Data processing and analysiswere performedwith SPSS Version
14.0 (SPSS Inc., Chicago, IL, U.S.A.). Statistical comparisons between
responders and non-responders used either Fisher’s exact tests, x2
tests or t-tests for independent samples. Variables associated with
responsiveness (p < 0.20) in bivariate analyses were entered in a
multivariable logistic regression model. This model was reduced
using a backward elimination procedure (a = 0.05). Odds ratios
(OR) and 95% conﬁdence intervals (CI) were calculated. The same
type of analyses was conducted using long-term seizure freedom
as the dependent variable. This time, response to VPA was
considered among the potential predictors. This study was
approved by the Research Ethical Committees of both CHU Sainte
Justine and CHU Sherbrooke.
3. Results
3.1. Study sample
One hundred and eighty patients identiﬁed as having CAE and
treated with VPA were included in this study. The mean age at
diagnosis was 7  2.94 years (range 9 months–14 years 8 months)
and 77 (42.8%) were male. Thirty-eight patients (21.1%) presented a
single GTCS, 9 (5%) presented a single myoclonic seizure and one
patient presented both. These other seizure types happened either
during treatment with VPA or following treatment withdrawal. One
hundred and sixty-three patients (90.6%)were givenVPA as a ﬁrst line
treatment. The remaining 17 (9.4%) were ﬁrst treated with ESM and
then switched to VPA for lack of efﬁcacy.
We had originally identiﬁed a total of 332 patients with
suspected absence seizures but we had to exclude 152 patients for
the following reasons: 12 presented brain lesions, 30 did not have
enough information in the ﬁles, 12 had CAE but treated with a
different AED, one had CAE andwas prescribed VPA but the parents
refused to give the treatment to their child and ﬁnally 97 were
treated with VPA but had a different diagnosis than CAE.
3.2. VPA efﬁcacy
Treatment with VPA led to seizure freedom in 112 (58.3%)
patients. As shown in Table 1, more patients refractory to VPA
experienced GTCS compared to responders and had a pre-
treatment seizure frequency greater than 10/day (with p  0.001
in both cases). Agewas also a factor signiﬁcantly linked to response
with patients in the responsive group being on average 16 months
older at time of seizure onset, diagnosis and treatment onset (data
shown in Table 2). However, the age at which the patients
experienced their GTCS did not impact on the response to VPA.
When all factors were combined in a multivariable logistic
regression analysis, we could not keep all time factors in the
equation because of co-linearity.We therefore chose to keep age at
diagnosis as the only time variable since age at seizure onset is
known to be less reliable since it is reported by the parents and
absences seizures can take some time to be recognized. In the ﬁnal
model shown in Table 3, all variables that were signiﬁcantly
correlated to VPA response at the 5% level in the univariate
analyses continued to be signiﬁcant in presence of each other. A
high seizure frequency (10/day) prior to treatment and the
presence of GTCS were both factors that increased the risk of non-
response to VPA with odds ratios of 3.1 and 4.1, respectively. A
higher age at diagnosis was a protective factor since it decreased
Table 3
Multivariable logistic regression analysis results for response to VPA.
Variable Coefﬁcients p-Value Adjusted odds ratios (ORA) CI95% for ORA
Seizure frequency 10/day before treatment 1.19 <0.001 3.296 1.73–6.27
Presence of GTCS 1.46 <0.001 4.324 1.92–9.74
Age at diagnosis 0.19 <0.001 0.830 0.78-0.89
CI, conﬁdence interval; GTCS, generalized tonic clonic seizures.
Table 1
Univariate comparison of categorical variables between responders and non-responders.
Factors Responders
(n=112)
Non-responders
(n=68)
Odds ratios
(OR)
CI95%for
OR
p-Value
Male gender (%) 46.4 36.8 1.49 0.80-2.76 0.204
Prematurity (%) 8.0 5.9 0.72 0.21-3.37 0.769
Prenatal history (%) 6.3 10.3 1.70 0.57-5.09 0.335
Family history of epilepsy (%) 42.3 50.0 1.36 0.74-2.50 0.318
Febrile convulsions (%) 15.3 8.8 0.54 0.20-1.43 0.208
Learning disability (%) 36.0 41.2 1.24 0.67-2.31 0.492
ADD or ADHD (%) 35.1 45.6 1.56 0.84-2.86 0.164
VPA blood concentration within therapeutic range (%) 77.6 66.7 1.74 0.75-4.01 0.195
Presence of other seizure types (%)
GTCS 13.4 33.8 3.30 1.58-6.93 0.001
Myoclonic 4.5 5.9 1.34 0.35-5.16 0.731
Both 0 1.5 1.02 0.99-1.04 0.378
Either 17.9 38.2 2.85 1.43-5.66 0.002
Seizure frequency 10/day before treatment (%) 27.0 52.9 3.04 1.61-5.73 <0.001
Long-term seizure freedom (%) 98.0 61.4 30.49 6.81-136.34 <0.001
CI, conﬁdence interval; prenatal history, problems that occurred during the pregnancy; ADD, attention deﬁcit disorder; family history of epilepsy, diagnosis of epilepsy in a
ﬁrst or second degree relative; ADHD, attention deﬁcit disorder with hyperactivity; VPA, valproic acid and GTCS, generalized tonic clonic seizures.
Table 2
Inﬂuence of time factors on response to VPA.
Responders (n=112) Non-responders (n=68) p-Value
Mean (SD) Range (y, mo) Mean (SD) Range (y, mo)
Age at onset of absences (years) 6.71 (2.89) 0.58–14.25 5.49 (2.78) 0.08–12.00 0.006
Age at diagnosis (years) 7.55 (2.95) 0.75–14.67 6.11 (2.72) 1.33–12.00 0.001
Age at onset of therapy (years) 7.58 (2.97) 0.75–14.67 6.16 (2.72) 1.33–12.00 0.001
Delay between start of seizures and treatment (months) 10.44 (15.22) 0.00–6.67 8.05 (11.79) 0.00–5.00 0.240
SD, standard deviation; y, years; mo, months.
Fig. 1.Outcome of patients included in the study. R represents the group of patients
who responded to VPA and NR represents patients who did not respond to VPA
treatment. The percentage represents the relative percentage of patients within the
group that are present in each outcome category with the speciﬁc n for each group
indicated on top of each bar.
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1. Gender did not affect VPA response rates. The maximum VPA
dosage as well as blood levels also did not correlate with response
to VPA or seizure freedom.
3.3. Long-term seizure outcome
Twenty-four patients were excluded from the analysis regard-
ing long-term outcome since these patients were still within their
two ﬁrst years of treatment at the end of the study period so we
cannot evaluate long-term seizure freedom for these patients. As
shown in Fig. 1, 45.2% of patients achieved seizure freedom and
remained so even after treatment withdrawal (58 out of 99 in the
VPA responsive group and 12 out of 57 in the non-response group;
p < 0.001). Sixty-one patients were also seizure free but continued
to takemedication (39 out of 99 in the responsive group and 22 out
of 57 in the non-responsive group). The patients who were not
seizure free took signiﬁcantlymore AEDs and continued to show an
abnormal EEG (data shown in Table 4). Also, they were more likely
to have a history of GTCS (more than twice the percentage of
responders; p = 0.003).
Thirty-ﬁve patients responded to a different AED after failing
VPA. The different treatment options and the number of patients
who responded to these are shown in Table 5. Ethosuximide (ESM)wasmost often the ﬁrst drug tried after VPA failure. It was effective
as a monotherapy in 8 out of 49 patients and in an additional 10
children in polytherapy. Lamotrigine (LTG) was also tried in 44
patients with four patients responding when given as a mono-
Table 4
Clinical variables linked to long-term seizure freedom.
Variable Seizure
free (n=132)
Not seizure
free (n=24)
p-Value
Response to VPA (%) 73.5 8.3 <0.001
Presence of GTCS (%) 18.2 45.8 0.003
Number of other AEDs
taken (mean)
0.8 2.4 <0.001
VPA, valproic acid;GTCS, generalized tonic clonic seizures;AEDs, anti-epilepticdrugs.
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ﬁve patients became seizure free. The remaining 33 patients did
not respond to any of the drugs tried over the study period.
4. Discussion
Themain ﬁnding in this study is that VPA response is associated
with long-term seizure freedom in our cohort of children with CAE
since 98.0% of responders were seizure free at the end of our study
period. In contrast, the patients who did not respond to VPA
treatment have a less favourable long-term outcome since more
than a third (39.3%) of these patients do not achieve good seizure
control with any AED treatment (p < 0.001).
4.1. Clinical factors predictive of VPA response
The main goal of our study was to deﬁne the clinical variables
that could help us predict VPA efﬁcacy in children with absence
seizures. Our sample resembles that of other hospital-based
studies even though our percentage of non-responders is in the
upper range of the previously reported response rates (32.2%
compared to 25–37%).1,5,8,21
Factors predicting a poor response to VPA in our study (Table 3)
are in accordancewith previous reports on the prognosis of CAE.5,11
TheoccurrenceofGTCS isknowntoworsen theprognosisof children
presentingwith absence seizures.8,11 A younger age at seizure onset
has also been associated with poor response to AED treatment.7,8
Age at seizure onset was not found to be linked to response to ﬁrst
AED in one study on absence seizures,5 but that study included
either treatment with VPA, ethosuximude (ESM) or carbamazepine
(CBZ).Webelieve that including threedifferent treatmentsmodiﬁed
the effect of certain variables, which could be predictive of response
to one drug but not to another. A large number of pre-treatment
seizures has already been associated with a poor response to
AEDs.1,21 We chose to evaluate the effect of frequency of using a
categorical model (more or less than 10 per day) instead of a linear
model since absence seizures occur several times a day and it is hardTable 5
Alternative treatments in patients who did not respond to VPA.
Treatment N tried Response
Monotherapy
Ethosuximide (Zarontin) 49 8 (16.3%)
Lamotrigine (Lamictal) 44 4 (9.1%)
Clobazam (Frisium) 16 1 (6.2%)
Topiramate (Topamax) 7 1 (14.3%)
Clonazepam (Rivotril) 17 1 (5.9%)
Levitiracetam (Keppra) 12 0 (0.0%)
Nitrazepam (Mogadon) 2 0 (0.0%)
Ace´tazolamide (Diamox) 6 0 (0.0%)
Cabamaze´pine (Te´gretol) 10 0 (0.0%)
Zonisamide (Zonegran) 2 0 (0.0%)
Oxcarbazepine (Trileptal) 1 0 (0.0%)
Pregabalin (Lyrica) 1 0 (0.0%)
Vigabatrin (Sabril) 1 0 (0.0%)
a Addition of one other drug.
b Addition of two other drugs.to determine exactly when the seizures began, especially in a
retrospective study. This method has also been previously used and
has shown to be associated with a poor prognosis.6 Finally, age at
diagnosis was also predictive with patients responding to VPA
treatment being on average 17.3 months older than the non-
responsivepatients at the timeofdiagnosis and14.6monthsolder at
the occurrence of the ﬁrst seizure. This is in accordance with
previous studies including one, which had responders that were 17
months older at seizure onset than non-responders.4We chose here
to take age at diagnosis instead of age at seizure onset as a predictor
variable because it is a more reliable value.
4.2. Clinical factors predictive of seizure freedom
Factors linked to long-term seizure freedom are the absence of
GTCS, response to VPA treatment and a low number of different
AEDs taken. We do realize that these factors are not readily
available at the ﬁrst visit. But as clinicians we can use these factors
to council parents about long-term outcome and improve
treatment observance.
We could not use the standard deﬁnitions for remission (2 year
or 5 year terminal remission) because this is a retrospective study
and once the patients were off their medication for a certain time
they did not come back to the epilepsy clinic unless they
experienced a recurrence. This is the reason why we identiﬁed
the group only as being seizure free for more than 2 years.
Failure of the ﬁrst AED is often considered to be a poor prognosis
for complete seizure control for pediatric partial epilepsy4,22 aswell
as for CAE.5,22 In our cohort, 90.6% were given VPA as a ﬁrst line
treatment and response to VPA was also strongly correlated with
seizure freedom with 98.0% of children responding to VPA being
seizure free at the end of the study. In contrast, non-respondershave
a less favorable long-term outcome. In the 17 patients that were
given ESM as the ﬁrst line treatment andwere switched to VPA due
to lack of efﬁcacy, 11 responded to VPA and achieved seizure
freedom. Four out of the six patients refractory to VPA as well, were
still able to achieve seizure freedom with another AED.
The poor outcome of non-responders to initial treatment might
be another clinical example that seizures beget seizures.23 But we
cannot rule out that children, who do not respond to VPA, could
also have a different form of epilepsy. For example it is known that
frontal lobe epilepsy can mimic absence seizures and have a
different outcome.24 We therefore intend to study the genetic
background of this cohort to search for seizure susceptibility genes
as well as genes implicated in pharmacoresistance.
In summary, the main difference in our study, compared to
those looking at drug responsiveness, is thatwe chose to look at the+1a +2b Total
8 (16.3%) 2 (4.1%) 18 (36.7%)
10 (22.7%) 2 (4.5%) 16 (36.3%)
2 (12.5%) 0 (0.0%) 3 (18.7%)
0 (0.0%) 1 (14.3%) 2 (28.6%)
0 (0.0%) 1 (5.9%) 2 (11.8%)
2 (16.7%) 0 (0.0%) 2 (16.7%)
1 (50.0%) 0 (0.0%) 1 (50.0%)
1 (16.7%) 0 (0.0%) 1 (16.7%)
0 (0.0%) 1 (10.0%) 1 (10.0%)
0 (0.0%) 0 (0.0%) 0 (0.0%)
0 (0.0%) 0 (0.0%) 0 (0.0%)
0 (0.0%) 0 (0.0%) 0 (0.0%)
0 (0.0%) 0 (0.0%) 0 (0.0%)
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disorder (i.e. CAE) and a single treatment. A number of studies
included patients with all types of epilepsies and then subdivided
them into each category,3,7,21 which diminishes the power of the
statistical analysis.
As our maximum age at follow-up was 18 years old, one might
argue that this might be insufﬁcient to assess complete remission
because it is well known that AS can still remit at a later age.11
However, the primary purpose of this study was to evaluate the
initial response to VPA. In addition, our study suffers from certain
biases and limits. First, it is a hospital-based study including
patients followed in a specialized epilepsy clinic and therefore a
selection bias toward refractory patients is expected. Some
patients with CAE might not come to our center or are seen in
the new diagnosis clinic but then followed by their pediatrician or
family doctor, so seizure and epilepsy outcome were not available.
The latter explanation was observed in 20 patients that were
excluded. If we hypothesize that these patients were all well
controlled on VPA, it could have increased our responder rate from
62.20% to 66.0%. We do realize that this calculation is highly
speculative but it is only to illustrate the impact of the choice of the
epilepsy clinic for the study. This bias therefore limits the
generalization of our results to the general population or children
with CAE. Also, we did not take into consideration race and
ethnicity data because these data are not readily available in the
patient’s ﬁles. It would have been interesting to have this
information since it is known that race and ethnicity can have
an impact on response and adverse effects to certain drugs.25 Also,
one of our four predictors of poor response to VPA is the pre-
treatment seizure frequency. This can be misleading since it is a
variable that cannot be precisely measured retrospectively. But we
believe that the amounts of seizures that are missed are low in
proportion to the number of seizures that are reported. Thus, by
categorizing the variable, we can speculate that the under-
estimation can be considered equal in both groups (low and high
seizures frequency). Finally, it is possible that our sample was not
homogeneous because some of the patients might have been miss
diagnosed as having CAE but in fact had JAE or CAE leading to JME
witch might have a distinct proﬁle and are known to be more
severe cases of epilepsy than simple CAE.
5. Conclusion
In conclusion, we found that the factors predicting resistance to
VPA were a younger age at time of diagnosis, a higher seizure
frequency prior to treatment and the presence of GTC seizures. We
now need to determine if these children have a different genetic
proﬁle than responders, as this might help us guide treatment and
improve long-term outcome.
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